Skip to Main Content

TWi Pharmaceuticals Protects Generic Drug

Client Success


Generic drug manufacturer TWi Pharmaceuticals (and its predecessor Anchen Pharmaceuticals) sought to market a generic version of Cephalon’s Amrix®—a medication used to help control muscle spasms associated with acute, painful musculoskeletal conditions. Cephalon filed suit alleging that TWi’s generic version infringed several patents.


We obtained a ruling that TWi did not infringe any patents. After the Court’s order in favor of TWi, our team filed a motion to deem the case exceptional and for recovery of attorneys’ fees. The Court granted our motion and awarded TWi its attorneys’ fees.


Stay updated.

Subscribe to receive Husch Blackwell’s news and insights.

Select your preferences